Shares of Guardant Health, Inc. (NASDAQ:GH – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-five research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, twenty-three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $183.7826.
A number of equities research analysts have issued reports on the stock. TD Cowen increased their price objective on shares of Guardant Health from $200.00 to $210.00 and gave the company a “buy” rating in a report on Friday, July 31st. Stifel Nicolaus boosted their target price on shares of Guardant Health from $130.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Guggenheim upped their target price on shares of Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Sanford C. Bernstein raised their target price on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, July 2nd. Finally, Mizuho lifted their price target on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st.
Read Our Latest Stock Analysis on Guardant Health
Guardant Health Trading Down 0.8%
Insider Activity
In other news, insider Chris Freeman sold 24,406 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the completion of the transaction, the insider owned 60,034 shares in the company, valued at $7,124,234.78. This trade represents a 28.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider John G. Saia sold 20,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total value of $2,130,200.00. Following the transaction, the insider owned 45,950 shares of the company’s stock, valued at $4,894,134.50. This represents a 30.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 674,445 shares of company stock valued at $88,073,291. 5.60% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Guardant Health
Institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC raised its position in shares of Guardant Health by 56.5% during the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock valued at $3,012,000 after buying an additional 25,831 shares in the last quarter. Empowered Funds LLC purchased a new position in Guardant Health in the first quarter worth about $274,000. Sei Investments Co. increased its stake in Guardant Health by 15.8% during the second quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock worth $4,023,000 after acquiring an additional 10,538 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Guardant Health by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock valued at $32,922,000 after purchasing an additional 54,284 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Guardant Health by 56.4% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock valued at $5,800,000 after purchasing an additional 40,209 shares during the period. Institutional investors own 92.60% of the company’s stock.
About Guardant Health
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Stories
- Five stocks we like better than Guardant Health
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
